Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.3555
+0.0655 (22.59%)
At close: Jun 24, 2025, 4:00 PM
0.3443
-0.0112 (-3.15%)
Pre-market: Jun 25, 2025, 7:00 AM EDT
Equillium Employees
Equillium had 35 employees as of December 31, 2024. The number of employees decreased by 9 or -20.45% compared to the previous year.
Employees
35
Change (1Y)
-9
Growth (1Y)
-20.45%
Revenue / Employee
$868,743
Profits / Employee
-$399,629
Market Cap
12.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
EQ News
- 7 weeks ago - Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - Business Wire
- 7 weeks ago - Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - Business Wire
- 2 months ago - Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
- 3 months ago - Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients - Benzinga
- 3 months ago - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Business Wire
- 3 months ago - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Business Wire
- 4 months ago - Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Business Wire
- 7 months ago - Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - Business Wire